AHG
BEARISH
$2.5
Live
Akso Health Group · NASDAQ
$0.83
52W Range
$2.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$2.14B
P/E
N/A
ROE
-68.3%
Profit margin
N/A
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
AHG's Piotroski F-Score of 5/9 indicates a stable but not strong financial position, with significant red flags in profitability and cash flow. The company reports a 0.00% profit margin, negative ROE of -68.29%, and a gross margin of just 1.00%, signaling deep operational inefficiencies. Despite a low debt/equity ratio and decent liquidity, the absence of positive earnings, free cash flow, and a lack of dividend support undermine long-term sustainability. The stock's price performance is driven by speculative momentum rather than fundamentals, with a Price/Sales of 144.30 far exceeding sector averages and no intrinsic value support.
Key Strengths
Low debt/equity ratio (0.01) indicates minimal financial leverage risk
Current ratio of 1.53 and quick ratio of 1.19 suggest adequate short-term liquidity
Recent price surge (85.2% in 1 week) reflects strong short-term market momentum
Quarterly earnings have shown occasional positive surprises (e.g., +150% in 2019-06-18)
Market cap of $2.14B places it in a mid-tier healthcare distribution segment
Key Risks
Negative ROE (-68.29%) and ROA (-1.42%) indicate severe capital inefficiency and losses
0.00% profit margin and -20.54% operating margin reveal fundamental business model flaws
No free cash flow or operating cash flow data available, raising liquidity sustainability concerns
Price/Sales of 144.30 is astronomically high compared to sector average (185.38) and peers, suggesting extreme overvaluation
Piotroski F-Score of 5/9 is below the threshold for strong financial health, with multiple profitability and cash flow failures
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
10
25
40
30
0
AI Verdict
Weak
Key drivers: Negative profitability metrics, Lack of cash flow generation, Extremely high valuation multiples, Unstable earnings history, Low Piotroski F-Score
Confidence
85%
Value
10/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- No Graham Number or intrinsic value available
- Price/Sales of 144.30 is unsustainable
- No P/E or PEG data to support valuation
- Trading at a massive premium to sector average
Future
25/100
Ref Growth rates
Positives
- Revenue growth of 0.90% YoY, slightly positive
- Recent price momentum suggests speculative interest
Watchpoints
- Earnings growth is -144.1% YoY
- Most recent Q/Q EPS growth is -400.0%
- No forward guidance or analyst coverage
Past
40/100
Ref Historical trends
Positives
- Some quarters beat estimates (e.g., 2018-02-13, 2018-06-15)
- Historical price has risen 547.7% over 3 years
Watchpoints
- Consistent negative earnings across all quarters
- Large negative surprises (e.g., -173.5% in 2018-12-03)
- Earnings volatility and regression
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity (0.01) and healthy current/quick ratios
Watchpoints
- Piotroski F-Score of 5/9 indicates weak financial health
- Negative ROE and ROA suggest poor capital use
- No Altman Z-Score available, but negative earnings and margins imply distress risk
- No free cash flow data raises solvency concerns
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend yield and payout ratio are N/A
- No dividend history or payment
- Negative earnings make dividend sustainability impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.5
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AHG and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AHG
Akso Health Group
Primary
|
+24.4% | +547.7% | +88.2% | +30.8% | +77.3% | +85.2% |
|
ACHC
Acadia Healthcare Company, Inc.
Peer
|
-61.4% | -66.0% | -16.5% | +8.2% | +51.5% | -8.2% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
AAPG
Ascentage Pharma Group Internat
Peer
|
+28.4% | +28.4% | +17.7% | -41.4% | -10.7% | -8.5% |
|
DAWN
Day One Biopharmaceuticals, Inc.
Peer
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
AHG
Akso Health Group
Primary
5Y
+24.4%
3Y
+547.7%
1Y
+88.2%
6M
+30.8%
1M
+77.3%
1W
+85.2%
ACH
Acadia Healthcare Company, Inc.
Peer
5Y
-61.4%
3Y
-66.0%
1Y
-16.5%
6M
+8.2%
1M
+51.5%
1W
-8.2%
BHC
Bausch Health Companies Inc.
Peer
5Y
-78.1%
3Y
-29.4%
1Y
-24.3%
6M
-12.7%
1M
-17.7%
1W
-15.3%
AAP
Ascentage Pharma Group Internat
Peer
5Y
+28.4%
3Y
+28.4%
1Y
+17.7%
6M
-41.4%
1M
-10.7%
1W
-8.5%
DAW
Day One Biopharmaceuticals, Inc.
Peer
5Y
-8.7%
3Y
+69.0%
1Y
+205.7%
6M
+189.6%
1M
+0.6%
1W
+0.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
10.82
P/S Ratio
144.3
EV/Revenue
432.29
EV/EBITDA
-4387.63
Market Cap
$2.14B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-20.54%
Gross Margin
1.0%
ROE
-68.29%
ROA
-1.42%
Growth
Revenue and earnings growth rates
Revenue Growth
+0.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
1.53
Good
Quick Ratio
1.19
Good
Cash/Share
$0.0
Quarterly Earnings History
EPS performance vs analyst estimates
2019-09-18
$-0.45
2019-06-18
$0.15
+150.0% surprise
2019-02-28
$-0.6
+23.1% surprise
2018-12-03
$-1.08
-173.5% surprise
Healthcare Sector Comparison
Comparing AHG against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-68.29%
This Stock
vs
-86.0%
Sector Avg
-20.6%
(Below Avg)
Debt to Equity
0.01
This Stock
vs
3.51
Sector Avg
-99.7%
(Less Debt)
Revenue Growth
0.9%
This Stock
vs
90.15%
Sector Avg
-99.0%
(Slower)
Current Ratio
1.53
This Stock
vs
3.67
Sector Avg
-58.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AHG
Akso Health Group
|
BEARISH | $2.14B | - | -68.3% | -% | $2.5 | |
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $2.17B | - | -41.0% | -33.3% | $23.52 | Compare |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | Compare |
|
AAPG
Ascentage Pharma Group Internat
|
BEARISH | $2.09B | - | -159.6% | -296.8% | $22.32 | Compare |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | Compare |
AHG
Akso Health Group
BEARISH
Mkt Cap
$2.1B
P/E
-
ROE
-68.3%
Price
$2.5
Past News Coverage
Recent headlines mentioning AHG from our newsroom.
Newest → oldest
No matching news yet.